By Sherry Hseih, Healthcare Editor
Meshkin’s venture fund is a “social entrepreneurship accelerator that is helping profound social problems.” Profound Ventures plans to make seed investments in the five- to low six-digits, starting with healthcare opportunities. The current portfolio includes technologies to help people age at home.
By Mary Corey, Reporter
He has rallied… to many causes, including fighting prejudice, hunger, homelessness, domestic violence and cancer… Brian's efforts have not gone unnoticed. This year he received a community service award from the United Way of Central Maryland and was named Maryland's young volunteer of the year by the Veterans of Foreign Wars.
By Vita Reed, Reporter
Brian Meshkin sought a way to help doctors make better decisions in the specialty of pain management, acting on the desire in 2009 when he created Irvine-based Proove Biosciences Inc. Meshkin, Proove’s founder and chief executive, was one of five winners honored by the Business Journal at its 15th annual Excellence in Entrepreneurship Awards at a March 10 luncheon at Hotel Irvine
By David Folkenflik, Now an NPR Correspondent
There's a simple answer: Above all, Meshkin appears to be a young man who believes fervently that The System works. His brief life seems to prove the cliches: If you play by the rules, work hard, keep your head down and fight for what you believe, you'll succeed. While canny enough to work the system, it's little wonder that Meshkin believes in it.
By Kathleen Bachynski, Angela Turi, and Alison Bateman-House
Eighth grader Brian Meshkin, who was on the scene of the crash that killed Kelley, led the students’ committee on bike helmet legislation. The group prepared surveys to document the need for a law, called newspapers and television stations to seek editorial support, and testified during a Howard County Council meeting.
As a result of their activism, the local council approved the new ordinance on May 7, 1990.
By Sajid Khan
SK: What advice would you offer to our readers who aspire to follow in your footsteps?
Brian: When starting a business, don’t try to do it based on a hypothesis or “if…then” statement. So many entrepreneurs say, “if” I can do this or that, “then” I will be able to do this or that. Such a hypothesis makes your business an experiment subject to conditions. Success has never been a condition, it has been a destination for me. Eliminate the “ifs” and focus on how to incrementally do the “thens”. By doing this, you won’t wait to do what is necessary to succeed.
Brian Meshkin is interviewed by Dr. Alan Beyer from Hoag Orthopedic Institute, a client of Proove Biosciences
Back in 2008, the San Diego Magazine chose Brian as an Honorable Mention in the Powers to Be in Biotechnology.
Brian Meshkin, President and CEO of Proove BioSciences joined Critical Mass Radio Show to how his firm is changing the future of medicine.
A social entrepreneur with innovative solutions to society’s most pressing social problems, Brian is an ambitious and persistent leader who lays out Proove’s vision and continues to lead the Company with dramatic revenue growth, disruptive technological innovations, a robust pipeline of new proprietary tests, and financial profitability.
Brian Meshkin founded Irvine, California-based Proove Biosciences in 2009. The company developed a portfolio of tests that can determine someone’s pain profile and tolerance to different pain medications to give doctors more information before prescribing medication.
By Dina Gusovsky
Sixty percent of the score a patient receives is based on testing for genetic markets associated with addiction, of which there are several, including COMT, dopamine receptors and the opioid MU1 receptor gene.
The other 40 percent of the addiction-risk score comes from personal factors: age, personal medical history, previous substance abuse and any history of depression (due to its links to drug use).
An Irvine biotech company is hoping to take on the nation’s opioid epidemic with a genetic test it says can identify patients who are predisposed to getting addicted to painkillers.
The problem is clear: Nearly 2 million people were found to be addicted to pain medication and nearly 19,000 people died from taking pain medication in 2014, according to the American Society of Addiction Medicine.
By Joe Burris
Meshkin advocated programs and practices implemented by the school system during his tenure, including digital education, processes to streamline the district's operations and a task force for student mental health. He also took part in board meetings via digital conference and said he engaged in efforts to establish transport for students taking evening and weekend classes.
By Sara Toth
Meshkin cited the growing success of his business — Proove Biosciences — as well as increasing time constraints therein, and a desire to spend more time with his family as reasons for his decision. "I do this with a heavy heart," he said. "I love serving my community. ... But there is a time and a season for everything, and at this stage in my life with a company based in California that is growing by leaps and bounds, and the precious time I am missing with my children, I must place the needs of my family first."
3 Time Award Winner, SmartCEO Magazine
The year Brian won the Emerging Technology Company CEO of the Year (2016)
Press conference with former Congresswoman Mary Bono and world leading expert in pain genetics, Dr. Luda Diatchenko, discussing Proove's award-winning data being presented at the American Academy of Pain Medicine annual meeting in Palm Springs
Proove Biosciences Downfall: What Happened? | 10x Medical Conference